Meeting
2024 ASCO Genitourinary Cancers Symposium
The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.
Authors
Yifu Shi
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
Yifu Shi , Xinyuan Wei , Fengnian Zhao , Jinge Zhao , Pengfei Shen , Ni Chen , Hao Zeng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 167)
DOI
10.1200/JCO.2024.42.4_suppl.167
Abstract #
167
Poster Bd #
G17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki-67.
First Author: Fengnian Zhao
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan
Poster
2024 ASCO Genitourinary Cancers Symposium
Quality of treatment with targeted agents for advanced prostate cancer by treating specialist.
First Author: Kassem S Faraj
Poster
2024 ASCO Genitourinary Cancers Symposium
Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.
First Author: Bobby Chi-Hung Liaw